{"prompt": "['2017N331008_06', 'CONFIDENTIAL', '208090', '9.', 'STATISTICAL CONSIDERATIONS', '9.1.', 'Statistical Hypotheses', 'This study is designed to show that the antiviral effect of switching to a simplified two-', 'drug regimen of DTG/3TC FDC once-daily is not inferior to continuation of their CAR at', 'week 48 in ART-experienced participants living with HIV-1.', 'Non-inferiority will be concluded if the upper bound of a two-sided 95% confidence', 'interval for the difference in virologic failure rates between the two treatment arms is', 'smaller than 5%. If rd is the virologic failure rate on DTG/3TC FDC and rris the virologic', 'failure rate on the CAR regimen, then the hypotheses can be written as follows:', '9.2.', 'Sample Size Determination', '9.2.1.', 'Sample Size Assumptions', 'The original sample size calculation required approximately 300 participants per arm', '(from a target of 857 screened participants) based on a true virologic failure rate of 2.25%', 'per arm, a non-inferiority margin of 4%, and a 2.5% one-sided significance level to', 'provide approximately 91% power to show non-inferiority for the proportion of', \"participants with virologic failure (per FDA's snapshot algorithm for assessing HIV-1\", 'RNA 50 c/mL) at Week 48.', 'The COVID-19 pandemic of 2019/2020 occurred during screening, and enrolment.', 'Because of the COVID-19 pandemic, there is potential impact on participant compliance', 'with study visits, study drug adherence, and data quality, and then consequently the', 'virologic failure rate could be higher than originally expected. With the increase of', 'assumed true virologic failure rate, we propose to change non-inferiority margin from 4%', 'to 5%. Assuming a virologic failure rate of 3%, a non-inferiority margin of 5%, and a', '2.5% one-sided significance level, a sample size of 245 participants per arm would', 'provide approximately 90% power to show non-inferiority for the proportion of', \"participants with virologic failure (per FDA's snapshot algorithm for assessing HIV-1\", 'RNA > 50 c/mL) at Week 48. Based on the sample size recalculation and both statistical', 'and practical considerations due to COVID-19 pandemic, a decision was made to', 'terminate the study enrolment. At the time of enrolment termination, approximately 445', 'participants were randomized and 53 were in screening. Assuming a 20% screen failure', 'rate the final number of participants is expected to be approximately 490 (245 per arm).', 'Rationale for non-inferiority margin', \"According to the FDA's 2015 guidance document (Human Immunodeficiency Virus-1\", 'Infection: Development of ART Drugs for Treatment, November 2015), the margin for', 'switch trials is driven by the largest clinically tolerable virologic failure rate and could be', 'from 4% to 6% depending on virologic failure rate. Per the FDA document, typical rates', 'of virologic failure seen in switch studies range from 1 to 3 percent and a margin of 4%', '69']['2017N331008_06', 'CONFIDENTIAL', '208090', 'for virologic failure rate was originally considered tolerable [CDER, 2015]. However due', 'to the COVID-19 pandemic, the virologic failure rate could be higher than originally', 'expected and hence the increase in the margin to 5%.', '9.2.1.1.', 'Response and virologic failure rate assumptions', 'Table 2 shows Snapshot response (HIV-1 RNA<50 c/mL) rates and Snapshot virologic', 'failure (HIV-1 RNA >50 c/mL) rates in previous switch studies in ART-experienced', 'participants living with HIV-1. Taken together and without considering the impact of the', 'COVID-19 pandemic, these data suggest that a reasonable assumption for the true failure', 'rate for the current ART control arm and the switch arm is 2.25%. Taking into', 'consideration of the impact of COVID-19, we assume a virologic failure rate of 3% in', 'both the CAR control arm and the switch arm.', '70']\n\n###\n\n", "completion": "END"}